Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 21Head & Neck 9Dermatologic 7Breast 4Lymphoid 3CNS 3Myeloid 2Genitourinary 2Gastrointestinal 2Other hematologic neoplasm 1Gynecologic 1

Conditions

Prostatic Neoplasms 6258Carcinoma, Renal Cell 1910Urinary Bladder Neoplasms 1669Kidney Neoplasms 929Breast Neoplasms 792Neoplasms 786Carcinoma, Transitional Cell 590Carcinoma, Non-Small-Cell Lung 522Neoplasm Metastasis 510Melanoma 484Ovarian Neoplasms 466Colorectal Neoplasms 451Lung Neoplasms 435Pancreatic Neoplasms 325Testicular Neoplasms 289Stomach Neoplasms 273Sarcoma 265Uterine Cervical Neoplasms 262Non-Muscle Invasive Bladder Neoplasms 262Head and Neck Neoplasms 241Colonic Neoplasms 217Esophageal Neoplasms 202Squamous Cell Carcinoma of Head and Neck 200Wilms Tumor 196Carcinoma, Hepatocellular 195Endometrial Neoplasms 188Recurrence 162Neuroblastoma 148Urologic Neoplasms 147Small Cell Lung Carcinoma 144

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Soft Tissue Neoplasms × Genitourinary × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT03159585 2020-01-22

To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors

Zhujiang Hospital

Phase 1 Completed
6 enrolled
BreastGastrointestinalGenitourinaryGynecologicHead & Neck

Urinary Bladder Neoplasms, Breast Neoplasms, Esophageal Neoplasms, Liver Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Soft Tissue Neoplasms, Stomach Neoplasms, Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡